BY13
BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR) ) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant. BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447) ; Blue: CRBN ligase ligand (HY-41547) ; Black: linker (HY-176226)
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Estrogen Receptor/ERR; PROTACs; Src
Related Pathways
Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Smiles
C/C(C1=NC=CC=C1)=N\NC2=NC(C=CC=C3)=C3N2C4CN(C4)C5CCN(CC5)C6=CC=CC7=C6C(N(C7=O)C8C(NC(CC8)=O)=O)=O
Molecular Formula
C35H35N9O4
Molecular Weight
645.71
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ERα; SRC-3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Protein Kinase, DNA Activated, Catalytic Polypeptide (PRKDC)
Recombinant Protein Kinase, DNA Activated, Catalytic Polypeptide (PRKDC)
Recombinant Protein Kinase, DNA Activated, Catalytic Polypeptide (PRKDC)